The European Commission, the EU executive arm, said on Monday it was discussing ways of ramping up the production capacity of Gilead Sciences Inc, the US company that produces remdesivir, the only drug granted a conditional marketing authorization by the EU for its use in COVID-19 patients.

"We do not have a huge inventory now, (it's) a few hundred doses that we have," Spahn said at a video-conference hearing organized by the European Parliament. Germany is the EU's largest country and currently holds the EU presidency.

Last week Spahn said Germany had sufficient reserves of remdesivir to treat the limited number of COVID-19 patients the country currently has.

He said boosting the drug's availability in Europe was not only a matter of acquiring doses from the company, but also of moving production to Europe.

Concerns over the availability of the drug increased after the US Department of Health and Human Services (HHS) said last week it had secured nearly all supplies of remdesivir over the next three months.

A spokesman for the European Commission told Reuters that on Monday the EU executive had talks with Gilead about its production capacity, but declined to elaborate as discussions were confidential.

Last week Brussels said it was in talks with Gilead to obtain doses of remdesivir for the 27 European Union countries.

Spahn urged Gilead to guarantee sufficient supplies to Europe.

"We expect from an international company like Gilead that you cannot just wish for access to the EU market and high prices for other products. I also expect supplies to Europe and into the European Union," he told lawmakers.

Spahn said he had discussed the matter with the US health secretary and with Gilead.

France's drugs regulator told Reuters on Monday it had taken steps with Gilead to obtain sufficient doses of remdesivir.

The Netherlands' health ministry said the country had sufficient doses of the drug at the moment, and Gilead had agreed to increase supplies in the near future.